3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
This article was originally published in The Pink Sheet Daily
Executive Summary
Projected U.S. approval triggers Chinese NDA for the anemia drug.
You may also be interested in...
AMAG Seeks Dialysis And Pre-Dialysis CKD Indication For Ferumoxytol
A potential competitor, Luitpold’s Injectafer, is scheduled to go before an FDA advisory committee Feb. 1.
Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter
Firm’s EPO product gains exclusive contract for 19 Chinese military hospitals in Q2.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.